L. Falchero

发表

Predictive factors of late radiation fibrosis: a prospective study in non-small cell lung cancer.

L. Claude, D. Pérol, C. Carrie, 2010, International journal of radiation oncology, biology, physics.

Efficacy and safety of anti-PD-1 immunotherapy in patients with advanced Non Small Cell Lung Cancer with BRAF, HER2 or MET mutation or RET-translocation. GFPC 01-2018.

P. Fournel, F. Guisier, C. Chouaid, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Primary sarcomas of the lung: a clinicopathologic study of 12 cases.

P. Souquet, R. Loire, J. Cordier, 2002, Lung cancer.

Second-line oral chemotherapy (lomustine, cyclophosphamide, etoposide) versus intravenous therapy (cyclophosphamide, doxorubicin, and vincristine) in patients with relapsed small cell lung cancer: a randomized phase II study of GFPC 0501.

C. Chouaid, R. Gervais, N. Baize, 2015, Clinical lung cancer.

FRESC: French Real world Extensive stage SCLC Cohorts: A retrospective study on patient characteristics and treatment strategy based on KBP-2010.

D. Pau, D. Debieuvre, L. Falchero, 2021, Lung cancer.

Doxycycline for prevention of erlotinib-induced rash in patients with non-small-cell lung cancer (NSCLC) after failure of first-line chemotherapy: A randomized, open-label trial.

C. Robert, G. Deplanque, O. Chosidow, 2016, Journal of the American Academy of Dermatology.

A multicenter phase II randomized trial of gemcitabine followed by erlotinib at progression, versus the reverse sequence, in vulnerable elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFPC 0505 study).

C. Chouaid, A. Vergnenègre, R. Corre, 2012, Lung cancer.

Bevacizumab in Combination with Platinum-Based Chemotherapy in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with or without Brain Metastases: A French Cohort Study (EOLE)

F. Bonnetain, C. Chouaid, J. Bennouna, 2017, Oncology.

A Randomized Open-Label Phase III Trial Evaluating the Addition of Denosumab to Standard First-Line Treatment in Advanced NSCLC: The European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOUR Trial

N. Reinmuth, U. Dafni, R. Stahel, 2020 .

Bevacizumab in Patients with Nonsquamous Non–Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study

J. Soria, J. Mazières, J. Trédaniel, 2015, Clinical Cancer Research.

Renal insufficiency is the leading cause of double maintenance (bevacizumab and pemetrexed) discontinuation for toxicity to advanced non-small cell lung cancer in real world setting.

B. Clarisse, P. Fournel, R. Gervais, 2015, Lung cancer.

Clinical Efficacy of Osimertinib in a Patient Presenting a Double EGFR L747S and G719C Mutation.

D. Arpin, L. Falchero, L. Boissiére, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Circulating free tumor-derived DNA to detect EGFR mutations in patients with advanced NSCLC: French subset analysis of the ASSESS study.

N. Normanno, O. Molinier, M. Denis, 2019, Journal of thoracic disease.

Cost analysis of erlotinib versus chemotherapy for first-line treatment of non-small-cell lung cancer in frail elderly patients participating in a prospective phase 2 study (GFPC 0505).

C. Chouaid, A. Vergnenègre, R. Corre, 2013, Clinical lung cancer.

Efficacy of Dabrafenib Plus Trametinib Combination in Patients with BRAF V600E-Mutant NSCLC in Real-World Setting: GFPC 01-2019

G. Jeannin, F. Guisier, G. Quéré, 2020, Cancers.

Characteristics of Lung Cancer in Patients Younger than 40 Years: A Prospective Multicenter Analysis in France

J. Mazières, C. Chouaid, H. Colineaux, 2018, Oncology.

First-line single-agent pembrolizumab for PD-L1-positive (tumor proportion score ≥ 50%) advanced non-small cell lung cancer in the real world: impact in brain metastasis: a national French multicentric cohort (ESCKEYP GFPC study)

P. Fournel, F. Guisier, R. Descourt, 2022, Cancer Immunology, Immunotherapy.

[Spontaneous resolution of multiorgan sarcoidosis associated with malignant lymphoma].

J. Guerin, L. Falchero, M. Pérol, 1998, Revue des maladies respiratoires.

Reasons Influencing Long-Term Anticoagulant Treatment Beyond 6 Months for Cancer-Associated Thrombosis in USCAT, A 432-Patient Retrospective Non-Interventional Study

S. Laporte, L. Bertoletti, C. Chapelle, 2021, Journal of cancer science and clinical therapeutics.

Long-Term Treatment of Cancer-Associated Thrombosis (CAT) Beyond 6 Months in the Medical Practice: USCAT, a 432-Patient Retrospective Non-Interventional Study

S. Laporte, L. Bertoletti, C. Chapelle, 2020, Cancers.

CYTAR: A randomized clinical trial evaluating the preventive effect of doxycycline on erlotinib-induced folliculitis in non-small cell lung cancer patients.

G. Deplanque, C. Robert, O. Chosidow, 2010 .

Failure of the Ottawa Score to Predict the Risk of Recurrent Venous Thromboembolism in Cancer Patients: The Prospective PREDICARE Cohort Study

A. Lamblin, S. Laporte, C. Chapelle, 2021, Thrombosis and Haemostasis.

Lung cancer trends and tumor characteristic changes over 20 years (2000–2020): Results of three French consecutive nationwide prospective cohorts’ studies

Nancy E. Marion, B. Delclaux, B. Asselain, 2022, The Lancet regional health. Europe.

Evidence of slight improvement in five-year survival in non-small-cell lung cancer over the last 10 years: Results of the French KBP-CPHG real-world studies.

B. Delclaux, B. Asselain, O. Molinier, 2019, Bulletin du cancer.

CheckMate 384: Phase IIIb/IV trial of nivolumab (nivo) 480 mg Q4W versus 240 mg Q2W after ≤ 12 months of nivo in previously treated advanced NSCLC.

N. Reinmuth, K. O'Byrne, S. Rabindran, 2019, Journal of Clinical Oncology.

Non-Small Cell Lung Cancer Patients Harboring HER2 Mutations: Clinical Characteristics and Management in a Real-Life Setting. Cohort HER2 EXPLORE GFPC 02–14

C. Chouaid, P. Dô, P. Thomas, 2019, Advances in Therapy.

[Pulmonary and musculo-cutaneous thigh actinomycosis].

J. Cordier, L. Falchero, F. Philit, 1997, Revue des maladies respiratoires.

Early variations of circulating interleukin-6 and interleukin-10 levels during thoracic radiotherapy are predictive for radiation pneumonitis.

J. Blay, V. Cottin, L. Claude, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer.

B. Milleron, M. Taron, G. Zalcman, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Multicenter phase II trial of nintedanib plus docetaxel in second-line treatment in advanced non-squamous non-small cell lung cancer patients refractory to first-line platin-based chemotherapy (REFRACT GFPC 02-15 study).

F. Guisier, A. Vergnenègre, I. Monnet, 2021, Lung cancer.

Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial.

C. Chouaid, R. Gervais, P. Saulnier, 2020, The Lancet. Oncology.

Patients with non-small-cell lung cancer harbouring a BRAF mutation: a multicentre study exploring clinical characteristics, management, and outcomes in a real-life setting: EXPLORE GFPC 02-14.

C. Chouaid, R. Gervais, A. Vergnenègre, 2018, Current oncology.

Clinical ACO phenotypes: Description of a heterogeneous entity

J. Vergnon, I. Court-Fortune, G. Devouassoux, 2019, Respiratory medicine case reports.

Respiratory failure with diffuse bronchiectases and cryoglobulinaemia

N. Girard, V. Cottin, A. Vasiljevic, 2008, European Respiratory Journal.

Brief Report: First-line Pembrolizumab in Metastatic Non-Small Cell Lung Cancer Habouring MET Exon 14 Skipping Mutation and PD-L1 ≥50% (GFPC 01-20 Study).

F. Guisier, H. Babey, R. Descourt, 2022, Clinical lung cancer.

Phase II trial of temozolomide and cisplatin followed by whole brain radiotherapy in non-small-cell lung cancer patients with brain metastases: a GLOT-GFPC study.

P. Souquet, R. Corre, G. Robinet, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

A multicentre phase II randomised trial of weekly docetaxel/gemcitabine followed by erlotinib on progression, vs the reverse sequence, in elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFPC 0504 study)

F. Barlesi, C. Chouaid, A. Vergnenègre, 2011, British Journal of Cancer.

An open multicenter phase II trial of weekly docetaxel for advanced-stage non-small-cell lung cancer in elderly patients with significant comorbidity and/or poor performance status: The GFPC 02-02b study.

F. Barlesi, P. Fournel, C. Chouaid, 2007, Lung cancer.

Second-line therapy with gefitinib in combination with docetaxel for advanced non-small cell lung cancer: a phase II randomized study

F. Barlesi, P. Souquet, P. Fournel, 2007, Targeted Oncology.

Use of a Comprehensive Geriatric Assessment for the Management of Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Phase III Randomized ESOGIA-GFPC-GECP 08-02 Study.

J. Daurès, B. Massuti, R. Descourt, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Definitive Prognostication System for Patients With Thoracic Malignancies Diagnosed With Coronavirus Disease 2019: An Update From the TERAVOLT Registry

V. Torri, N. Reinmuth, H. Wakelee, 2022, Journal of Thoracic Oncology.

P. Fournel, F. Guisier, R. Descourt, 2022, Cancer Immunology, Immunotherapy.

Real-life efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer harboring EGFR T790M mutation.

D. Planchard, F. Guisier, M. Wislez, 2019, Lung cancer.

Oral Vinorelbine and Cisplatin with Concurrent Radiotherapy After Induction Chemotherapy with Cisplatin and Docetaxel for Patients with Locally Advanced Non-small Cell Lung Cancer: The GFPC 05-03 Study

F. Barlesi, P. Fournel, R. Descourt, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Chronic Airways Assessment Test: psychometric properties in patients with asthma and/or COPD

Sudhir R Parikh, I. Pavord, Wei Zhang, 2023, Respiratory Research.

A randomised open-label phase III trial evaluating the addition of denosumab to standard first-line treatment in advanced NSCLC - the ETOP and EORTC SPLENDOUR trial.

N. Reinmuth, U. Dafni, R. Stahel, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Randomized open-label non-comparative multicenter phase II trial of sequential erlotinib and docetaxel versus docetaxel alone in patients with non-small-cell lung cancer after failure of first-line chemotherapy: GFPC 10.02 study.

A. Labrunie, P. Fournel, R. Descourt, 2014, Lung cancer.

Cost-utility analysis of maintenance therapy with gemcitabine or erlotinib vs observation with predefined second-line treatment after cisplatin–gemcitabine induction chemotherapy for advanced NSCLC: IFCT-GFPC 0502-Eco phase III study

G. Zalcman, P. Fournel, D. Pérol, 2012, BMC Cancer.

Management and outcomes of non–small cell lung cancer patients with rapid progression under second‐or‐more‐line immune checkpoint inhibitors: ERORECI study (GFPC 2016‐04)

F. Guisier, A. Vergnenègre, P. Dô, 2019, Cancer medicine.

A prospective study on radiation pneumonitis following conformal radiation therapy in non-small-cell lung cancer: clinical and dosimetric factors analysis.

David Pérol, Chantal Ginestet, Line Claude, 2004, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Efficacy of Pemetrexed as Second-Line Therapy in Advanced NSCLC after Either Treatment-Free Interval or Maintenance Therapy with Gemcitabine or Erlotinib in IFCT-GFPC 05-02 Phase III Study

F. Barlesi, P. Fournel, C. Chouaid, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Randomized phase III study of nivolumab and ipilimumab versus carboplatin-based doublet in first-line treatment of PS 2 or elderly (≥ 70 years) patients with advanced non–small cell lung cancer (Energy-GFPC 06-2015 study).

F. Guisier, C. Audigier-Valette, A. Vergnenègre, 2022, Journal of Clinical Oncology.

37P Sotorasib-induced liver and non-liver toxicity associated with sequential sotorasib following anti-PD(L)1 in KRASG12C mutant lung cancer

C. Mascaux, V. Gounant, A. Lemaitre, 2022, Annals of Oncology.

Phase III randomized study of carboplatin pemetrexed with or without bevacizumab with initial versus “at progression” cerebral radiotherapy in advanced non squamous non-small cell lung cancer with asymptomatic brain metastasis

R. Gervais, A. Vergnenègre, G. Robinet, 2021, Therapeutic advances in medical oncology.

Chronic Airways Assessment Test: psychometric properties in patients with asthma and/or COPD

Sudhir R Parikh, I. Pavord, M. Zhang, 2023, Respiratory Research.

P-700 Early variations of circulating interleukin-6 and interleukin-10 levels during thoracic radiotherapy are predictive for radiation pneumonitis in patients with non-small cell lung cancer: A prospective study

J. Blay, V. Cottin, L. Claude, 2005 .

A randomised phase III trial evaluating the addition of denosumab to standard first-line treatment in advanced NSCLC: The ETOP and EORTC SPLENDOUR trial.

N. Reinmuth, U. Dafni, R. Stahel, 2018, Annals of Oncology.